Developer docs
API playgroundTry for free, no card

Search company profiles

DevPro Biopharma

Full company profile

uuid000kpo9

Namestring
DevPro Biopharma
Legal namestring
DevPro Biopharma
Company typeenum
Private
Founded yearint
2020
Descriptiontext

DevPro Biopharma is a private clinical research and development accelerator founded in 2020 and headquartered in Basking Ridge, New Jersey. The company designs, develops, and delivers molecules into respiratory medicines through strategic partnerships with pharmaceutical companies and venture capital firms, offering full-lifecycle development from concept through global regulatory approvals with agencies including the FDA, EMA, PMDA, MHRA, Health Canada, TGA, and NMPA. Headcount is reported at 11-50 employees.

The firm's technical platform is focused on respiratory therapeutics, with proprietary development efforts in metered-dose inhaler (MDI) technology. Notable technology components include eco-friendly HFO-1234ze propellant inhalation solutions developed in partnership with Bespak, and next-generation low-emission respiratory inhaler technology powered by Honeywell. The team's historical track record includes contributions to more than 50 approved products or label expansions over the past 30 years across multiple therapeutic areas, including flagship respiratory products BEVESPI AEROSPHERE and BREZTRI AEROSPHERE developed with AstraZeneca. The active clinical pipeline targets COPD, asthma, pulmonary hypertension, idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, cystic fibrosis, and alpha-1 antitrypsin deficiency.

DevPro operates a B2B, sales-led go-to-market model, generating revenue through professional services for clinical development and licensing/milestone arrangements for co-developed new molecular entities. Pricing is quote-based and not publicly disclosed. The company does not commercialize end products directly; rather, distribution of approved therapies is handled through pharmaceutical partners' existing global networks. Customer segments center on pharmaceutical companies and VC investors seeking de-risked assets and development expertise, with respiratory disease patients as the end-user beneficiaries of the resulting medicines.

Short descriptiontext

DevPro Biopharma is a private clinical research and development accelerator that partners with pharmaceutical companies and VCs to design, develop, and deliver respiratory molecules into globally approved medicines, with deep expertise in metered-dose inhaler technology and regulatory submissions across FDA, EMA, and PMDA jurisdictions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBasking Ridge, United States
HQ citystring
Basking Ridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical development services, respiratory therapeutics, metered dose inhaler, pharmaceutical development, regulatory submissions
Industry2 codes
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Clinical Development Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Strategic Partnership Development
TypeLicensing Royalties
Description

Revenue generated through strategic partnerships with pharmaceutical companies and VCs for co-development of new molecular entities, with potential milestone payments and licensing arrangements

devprobiopharma.com
2Clinical Development Services
TypeProfessional Services
Description

Full development activities from concept through regulatory approvals, creating value through de-risked assets, accelerated timelines, and lower costs for partners

devprobiopharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

DevPro Biopharma is a clinical research and development accelerator that partners with pharmaceutical companies and venture capital firms to design, develop, and deliver molecules into approved medicines. Its core work spans the full clinical development lifecycle for respiratory therapeutics, including clinical trials, global regulatory submissions, and co-development of eco-friendly inhalation technologies such as HFO-1234ze-based metered dose inhalers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • More than 50 approved products or label expansions over 30 years
+2 more records
Product overview1 text field

DevPro Biopharma is a clinical development services company focused on bringing molecules into medicines through innovation, flexibility, and efficiency. The company offers development expertise spanning from concept through global regulatory approvals, with a focus on respiratory therapeutics. Their portfolio includes contributions to approved products such as BEVESPI AEROSPHERE® and BREZTRI AEROSPHERE™, as well as development of next-generation low-emission respiratory inhalers. DevPro's clinical development platform enables strategic partnerships with pharmaceutical companies and VCs to de-risk assets, accelerate timelines, and lower development costs.

Product and service3 records
1Clinical Development Services for Respiratory Therapeutics
CategoryClinical Development Services
Description

End-to-end clinical research and development services including clinical trial design, execution, regulatory submissions, and global approvals for pharmaceutical and VC partners developing respiratory therapies.

2Next-Generation Low-Emission Respiratory Inhaler
CategoryInhalation Drug Delivery Technology
Description

An eco-friendly respiratory inhaler platform powered by Honeywell technology with reduced global warming potential, developed as an alternative to traditional CFC inhalers for respiratory drug delivery.

3HFO-1234ze Propellant Inhalation Solution
CategoryInhalation Drug Delivery Technology
Description

Eco-friendly metered dose inhaler propellant solution using HFO-1234ze developed in partnership with Bespak to address the phase-out of CFC inhalers and meet demand for environmentally responsible respiratory devices.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-07
Description

DevPro Biopharma and Bespak are developing eco-friendly inhalation solutions using HFO-1234ze propellant as a sustainable alternative to CFC inhalers. This partnership addresses the phase-out of CFC inhalers and contributes to the growing demand for environmentally responsible respiratory care devices. The collaboration positions DevPro in the emerging market for next-generation metered dose inhalers.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-02
Description

Honeywell technology powers DevPro Biopharma's next-generation low-emission respiratory inhaler. This partnership enables development of environmentally friendly inhalation solutions with reduced global warming potential. Honeywell's technology expertise combined with DevPro's respiratory development capabilities supports innovation in sustainable respiratory drug delivery.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Mid-to-large CRO with strong specialty pharma and biotech focus, known for full-service clinical development. Comparable outsourced development model targeting pharma/biotech sponsors across therapeutic areas.

TypeDirect peer
Description

Mid-size global CRO with deep specialty pharma and respiratory therapeutic expertise, offering outsourced clinical development services to pharma and biotech sponsors. Closely comparable in size, therapeutic focus, and B2B development-services model.

TypeDirect peer
Description

Specialty CDMO focused on inhaled drug delivery and combination drug-device development (formed from the merger of 3M Drug Delivery Systems and Vectura). Directly comparable for inhaled respiratory development capabilities and propellant/device expertise.

TypeDirect peer
Description

Contract development and manufacturing organization with strong inhalation and respiratory drug formulation capabilities. Comparable as an outsourced development partner for inhaled therapeutics spanning formulation through clinical supply.

TypeDirect peer
Description

Global leader in drug delivery device development including metered dose inhalers, dry powder inhalers, and nasal sprayers. Directly comparable for inhaler device technology and respiratory drug delivery partnerships.

TypeBroad incumbent
Description

Largest global CRO and life sciences services provider offering end-to-end clinical development across all therapeutic areas. Sets the competitive benchmark on scale, geographic reach, and integrated services that DevPro competes against.

TypeBroad incumbent
Description

Large global CRO providing outsourced drug development and clinical research services. Competes with DevPro for pharma outsourced development work, particularly on multi-region respiratory programs.

TypeBroad incumbent
Description

Clinical and commercial solutions provider offering biopharma development services including clinical research and post-launch commercialization. Comparable outsourced model serving pharma and biotech sponsors.

TypeEmerging player
Description

Late-stage clinical biopharma focused on respiratory diseases including COPD and cystic fibrosis. Comparable respiratory therapeutic focus and inhaled drug development, though as an asset-owning sponsor rather than a services partner.

TypeEmerging player
Description

Late-stage respiratory biopharmaceutical company developing inhaled therapies for serious lung diseases. Comparable respiratory therapeutic focus and inhalation-based development approach as a peer sponsor in the pulmonology space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DevPro Biopharma

Pharmaceutical Clinical Development Servicesdevprobiopharma.com

DevPro Biopharma is a private clinical research and development accelerator that partners with pharmaceutical companies and VCs to design, develop, and deliver respiratory molecules into globally approved medicines, with deep expertise in metered-dose inhaler technology and regulatory submissions across FDA, EMA, and PMDA jurisdictions.

What DevPro Biopharma does

DevPro Biopharma is a private clinical research and development accelerator founded in 2020 and headquartered in Basking Ridge, New Jersey. The company designs, develops, and delivers molecules into respiratory medicines through strategic partnerships with pharmaceutical companies and venture capital firms, offering full-lifecycle development from concept through global regulatory approvals with agencies including the FDA, EMA, PMDA, MHRA, Health Canada, TGA, and NMPA. Headcount is reported at 11-50 employees.

The firm's technical platform is focused on respiratory therapeutics, with proprietary development efforts in metered-dose inhaler (MDI) technology. Notable technology components include eco-friendly HFO-1234ze propellant inhalation solutions developed in partnership with Bespak, and next-generation low-emission respiratory inhaler technology powered by Honeywell. The team's historical track record includes contributions to more than 50 approved products or label expansions over the past 30 years across multiple therapeutic areas, including flagship respiratory products BEVESPI AEROSPHERE and BREZTRI AEROSPHERE developed with AstraZeneca. The active clinical pipeline targets COPD, asthma, pulmonary hypertension, idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, cystic fibrosis, and alpha-1 antitrypsin deficiency.

DevPro operates a B2B, sales-led go-to-market model, generating revenue through professional services for clinical development and licensing/milestone arrangements for co-developed new molecular entities. Pricing is quote-based and not publicly disclosed. The company does not commercialize end products directly; rather, distribution of approved therapies is handled through pharmaceutical partners' existing global networks. Customer segments center on pharmaceutical companies and VC investors seeking de-risked assets and development expertise, with respiratory disease patients as the end-user beneficiaries of the resulting medicines.

DevPro Biopharma firmographics

Firmographics
Name
DevPro Biopharma
Legal name
DevPro Biopharma
Website
https://devprobiopharma.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
DevPro Biopharma is a private clinical research and development accelerator that partners with pharmaceutical companies and VCs to design, develop, and deliver respiratory molecules into globally approved medicines, with deep expertise in metered-dose inhaler technology and regulatory submissions across FDA, EMA, and PMDA jurisdictions.
Ownership category
akta.pro rank

DevPro Biopharma industry classification

Industry
Product category
Pharmaceutical Clinical Development Services
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Clinical development services
  • Respiratory therapeutics
  • Metered dose inhaler
  • Pharmaceutical development
  • Regulatory submissions

Where DevPro Biopharma is headquartered

Location

Headquarters

HQ city
Basking Ridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

DevPro Biopharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Strategic Partnership Development: Revenue generated through strategic partnerships with pharmaceutical companies and VCs for co-development of new molecular entities, with potential milestone payments and licensing arrangements
  2. Clinical Development Services: Full development activities from concept through regulatory approvals, creating value through de-risked assets, accelerated timelines, and lower costs for partners

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

DevPro Biopharma product offering

Product offering

Core offering

DevPro Biopharma is a clinical research and development accelerator that partners with pharmaceutical companies and venture capital firms to design, develop, and deliver molecules into approved medicines. Its core work spans the full clinical development lifecycle for respiratory therapeutics, including clinical trials, global regulatory submissions, and co-development of eco-friendly inhalation technologies such as HFO-1234ze-based metered dose inhalers.

Product overview

DevPro Biopharma is a clinical development services company focused on bringing molecules into medicines through innovation, flexibility, and efficiency. The company offers development expertise spanning from concept through global regulatory approvals, with a focus on respiratory therapeutics. Their portfolio includes contributions to approved products such as BEVESPI AEROSPHERE® and BREZTRI AEROSPHERE™, as well as development of next-generation low-emission respiratory inhalers. DevPro's clinical development platform enables strategic partnerships with pharmaceutical companies and VCs to de-risk assets, accelerate timelines, and lower development costs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Clinical Development Services for Respiratory Therapeutics End-to-end clinical research and development services including clinical trial design, execution, regulatory submissions, and global approvals for pharmaceutical and VC partners developing respiratory therapies.
  • Next-Generation Low-Emission Respiratory Inhaler An eco-friendly respiratory inhaler platform powered by Honeywell technology with reduced global warming potential, developed as an alternative to traditional CFC inhalers for respiratory drug delivery.
  • HFO-1234ze Propellant Inhalation Solution Eco-friendly metered dose inhaler propellant solution using HFO-1234ze developed in partnership with Bespak to address the phase-out of CFC inhalers and meet demand for environmentally responsible respiratory devices.

Quantifiable outcome

  • More than 50 approved products or label expansions over 30 years
  • +2 more outcomes

Companies that use DevPro Biopharma

Customer profile

Segments3 records

Ideal customer profiles2 records

DevPro Biopharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

DevPro Biopharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • BespakcoreTechnology or Integration · 7 May 2026DevPro Biopharma and Bespak are developing eco-friendly inhalation solutions using HFO-1234ze propellant as a sustainable alternative to CFC inhalers. This partnership addresses the phase-out of CFC inhalers and contributes to the growing demand for environmentally responsible respiratory care devices. The collaboration positions DevPro in the emerging market for next-generation metered dose inhalers.
  • HoneywellcoreTechnology or Integration · 2 October 2025Honeywell technology powers DevPro Biopharma's next-generation low-emission respiratory inhaler. This partnership enables development of environmentally friendly inhalation solutions with reduced global warming potential. Honeywell's technology expertise combined with DevPro's respiratory development capabilities supports innovation in sustainable respiratory drug delivery.

Scale indicators1 record

Recent moves3 records

Expansion highlights5 records

DevPro Biopharma competitors and assessment

Company assessment

Broad incumbents

  • Medpace: Mid-to-large CRO with strong specialty pharma and biotech focus, known for full-service clinical development. Comparable outsourced development model targeting pharma/biotech sponsors across therapeutic areas.
  • IQVIA: Largest global CRO and life sciences services provider offering end-to-end clinical development across all therapeutic areas. Sets the competitive benchmark on scale, geographic reach, and integrated services that DevPro competes against.
  • ICON plc: Large global CRO providing outsourced drug development and clinical research services. Competes with DevPro for pharma outsourced development work, particularly on multi-region respiratory programs.
  • Syneos Health: Clinical and commercial solutions provider offering biopharma development services including clinical research and post-launch commercialization. Comparable outsourced model serving pharma and biotech sponsors.

Direct peers

  • Worldwide Clinical Trials: Mid-size global CRO with deep specialty pharma and respiratory therapeutic expertise, offering outsourced clinical development services to pharma and biotech sponsors. Closely comparable in size, therapeutic focus, and B2B development-services model.
  • Kindeva Drug Delivery: Specialty CDMO focused on inhaled drug delivery and combination drug-device development (formed from the merger of 3M Drug Delivery Systems and Vectura). Directly comparable for inhaled respiratory development capabilities and propellant/device expertise.
  • Hovione: Contract development and manufacturing organization with strong inhalation and respiratory drug formulation capabilities. Comparable as an outsourced development partner for inhaled therapeutics spanning formulation through clinical supply.
  • Aptar Pharma: Global leader in drug delivery device development including metered dose inhalers, dry powder inhalers, and nasal sprayers. Directly comparable for inhaler device technology and respiratory drug delivery partnerships.

Emerging players

  • Verona Pharma: Late-stage clinical biopharma focused on respiratory diseases including COPD and cystic fibrosis. Comparable respiratory therapeutic focus and inhaled drug development, though as an asset-owning sponsor rather than a services partner.
  • Insmed: Late-stage respiratory biopharmaceutical company developing inhaled therapies for serious lung diseases. Comparable respiratory therapeutic focus and inhalation-based development approach as a peer sponsor in the pulmonology space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

DevPro Biopharma social profiles

Digital presence

DevPro Biopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DevPro Biopharma leadership team

Management profile

Number of profiles

DevPro Biopharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DevPro Biopharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DevPro Biopharma

What does DevPro Biopharma do?

DevPro Biopharma is a clinical research and development accelerator that partners with pharmaceutical companies and venture capital firms to design, develop, and deliver molecules into approved medicines. Its core work spans the full clinical development lifecycle for respiratory therapeutics, including clinical trials, global regulatory submissions, and co-development of eco-friendly inhalation technologies such as HFO-1234ze-based metered dose inhalers.

Is DevPro Biopharma a public or private company?

DevPro Biopharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was DevPro Biopharma founded?

DevPro Biopharma was founded in 2020. It employs 51 to 100 people.

Where is DevPro Biopharma based?

DevPro Biopharma is headquartered in Basking Ridge, United States, in the North America region.

How does DevPro Biopharma make money?

Two revenue lines are on record. Strategic Partnership Development is the primary driver. The others are clinical Development Services.

Who are DevPro Biopharma's main competitors?

Broad incumbents on record are Medpace, IQVIA, ICON plc and Syneos Health. Direct peers are Worldwide Clinical Trials, Kindeva Drug Delivery, Hovione and Aptar Pharma. Emerging players are Verona Pharma and Insmed.

Does DevPro Biopharma have an API?

No public API is recorded for DevPro Biopharma.

What industry is DevPro Biopharma in?

DevPro Biopharma's product category is Pharmaceutical Clinical Development Services. Its primary akta.pro industry code is HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals, with a secondary code of HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales